Scalable 96-well plate based iPSC culture and production using a robotic liquid handling system

Journal of Visualized Experiments

Volumn 2015, Issue 99, 2015, Pages

  Conway, Michael K ^a   Gerger, Michael J ^a   Balay, Erin E ^a   O’Connell, Rachel ^a   Hanson, Seth ^b   Daily, Neil J ^a   Wakatsuki, Tetsuro ^a  

^a InvivoSciences Inc

^b Gilson Inc   (United States)

Author keywords

96 well; Automated stem cell culture; Developmental biology; High throughput; IPSC; Issue 99; Liquid handling; Robotic; Scalable; Stem cell

Indexed keywords

ADIPOSE TISSUE; CELL CULTURE TECHNIQUE; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; DEVICES; FIBROBLAST; HIGH THROUGHPUT SCREENING; HUMAN; INDUCED PLURIPOTENT STEM CELL; PHYSIOLOGY; PLURIPOTENT STEM CELL; PROCEDURES; ROBOTICS;

ADIPOSE TISSUE; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE; FIBROBLASTS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PLURIPOTENT STEM CELLS; ROBOTICS;

EID: 84940599811     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/52755     Document Type: Article

References (51)

1. Takahashi, K., Okita, K., Nakagawa, M., Yamanaka, S. Induction of pluripotent stem cells from fibroblast cultures. Nature protocols. 2, (12), 3081-3089 (2007).
2. Grskovic, M., Javaherian, A., Strulovici, B., Daley, G. Q. Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nature reviews. Drug discovery. 10, 915-929 (2011).
3. Shi, Y. Induced pluripotent stem cells, new tools for drug discovery and new hope for stem cell therapies. Current Molecular Pharmacology. 2, 15-18 (2009).
4. Xu, X., Zhong, Z. Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Nature Publishing Group. 34, (6), 755-764 (2013).
5. Kirouac, D. C., Zandstra, P. W. The systematic production of cells for cell therapies. Cell stem cell. 3, (4), 369-381 (2008).
6. Ebert, P., Liang, J. W. Induced Pluripotent Stem Cells as a Disease Modeling and Drug Screening Platform. Journal of Cardiovascular Pharmacology. 60, (4), 408-416 (2012).
7. Pa Lalit, Hei, D. J., Raval, A. N., Kamp, T. J. Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. Circulation research. 114, 1328-1345 (2014).
8. Compagnucci, C., Nizzardo, M., Corti, S., Zanni, G., Bertini, E. In vitro neurogenesis: development and functional implications of iPSC technology. Cellular and Molecular Life Sciences. 1-17 (2013).
9. Yi, F., Liu, G. -H., Belmonte, J. C. I. Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy. Protein & Cell. 3, 246-250 (2012).
10. Mummery, C. L., Zhang, J., Ng, E. S., Elliott, D. A, Elefanty, aG., Kamp, T. J. Differentiation of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells to Cardiomyocytes: A Methods Overview. Circulation Research. 111, (3), 344-358 (2012).
11. Okano, H., et al. Steps toward safe cell therapy using induced pluripotent stem cells. Circulation Research. 112, 523-533 (2013).
12. Scheiner, Z. S., Talib, S., Feigal, E. G. The Potential for Immunogenicity of Autologous Induced Pluripotent Stem Cell-derived Therapies. The Journal of biological chemistry. 289, 4571-4577 (2014).
13. Sun, N., et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Science translational medicine. 4, (130), 130ra47 (2012).
14. Gunaseeli, I., Doss, M. X., Antzelevitch, C., Hescheler, J., Sachinidis, A. Induced pluripotent stem cells as a model for accelerated patientand disease-specific drug discovery. Current medicinal chemistry. 17, 759-766 (2010).
15. Zweigerdt, R. Large scale production of stem cells and their derivatives. Advances in Biochemical Engineering/Biotechnology. 114, 201-235 (2009).
16. Serra, M., Brito, C., Correia, C., Alves, P. M. Process engineering of human pluripotent stem cells for clinical application. Trends in Biotechnology. 30, 350-359 (2012).
17. Lock, L. T., Tzanakakis, E. S. Stem/Progenitor cell sources of insulin-producing cells for the treatment of diabetes. Tissue engineering. 13, 1399-1412 (2007).
18. Jing, D., Parikh, A., Canty, J. M., Tzanakakis, E. S. Stem cells for heart cell therapies. Tissue engineering. Part B, Reviews. 14, 393-406 (2008).
19. Soldner, F., Jaenisch, R. iPSC Disease Modeling. Science. 338, 1155-1156 (2012).
20. Olmer, R., et al. Long term expansion of undifferentiated human iPS and ES cells in suspension culture using a defined medium. Stem cell research. 5, (1), 51-64 (2010).
21. Wang, Y., Chou, B. -K., Dowey, S., He, C., Gerecht, S., Cheng, L. Scalable expansion of human induced pluripotent stem cells in the defined xeno-free E8 medium under adherent and suspension culture conditions. Stem cell research. 11, (3), 1103-1116 (2013).
22. Chen, V. C., et al. Scalable GMP compliant suspension culture system for human ES cells. Stem cell research. 8, (3), 388-402 (2012).
23. Amit, M., Laevsky, I., Miropolsky, Y., Shariki, K., Peri, M., Itskovitz-Eldor, J. Dynamic suspension culture for scalable expansion of undifferentiated human pluripotent stem cells. Nature protocols. 6, (5), 572-579 (2011).
24. Olmer, R., et al. Suspension Culture of Human Pluripotent Stem Cells in Controlled. Stirred Bioreactors. Tissue engineering. Part C. 18, (10), (2012).
25. Kehoe, D. E., Jing, D., Lock, L. T., Tzanakakis, E. S., Ph, D. Scalable Stirred-Suspension Bioreactor Culture. Tissue engineering. Part A. 16, (2), (2010).
26. Oh, S. K. W., et al. Long-term microcarrier suspension cultures of human embryonic stem cells. Stem Cell Research. 2, 219-230 (2009).
27. Chen, A. K. -L., Reuveny, S., Oh, S. K. W. Application of human mesenchymal and pluripotent stem cell microcarrier cultures in cellular therapy: achievements and future direction. Biotechnology advances. 31, 1032-1046 (2013).
28. Yang, H. S., Jeon, O., Bhang, S. H., Lee, S. -H., Kim, B. -S. Suspension culture of mammalian cells using thermosensitive microcarrier that allows cell detachment without proteolytic enzyme treatment. Cell transplantation. 19, 1123-1132 (2010).
29. Zweigerdt, R., Olmer, R., Singh, H., Haverich, A., Martin, U. Scalable expansion of human pluripotent stem cells in suspension culture. Nature. 6, (5), (2011).
30. Kami, D., et al. Large-scale cell production of stem cells for clinical application using the automated cell processing machine. BMC biotechnology. 13, 102 (2013).
31. Hussain, W., Moens, N., Veraitch, F. S., Hernandez, D., Mason, C., Lye, G. J. Reproducible culture and differentiation of mouse embryonic stem cells using an automated microwell platform. Biochemical engineering journal. 77, (100), 246-257 (2013).
32. Tandon, N., Marolt, D., Cimetta, E., Vunjak-Novakovic, G. Bioreactor engineering of stem cell environments. Biotechnology Advances. 31, 1020-1031 (2013).
33. Sun, N., et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proceedings of the National Academy of Sciences of the United States of America. 106, 15720-15725 (2009).
34. Ludwig, T. E., Bergendahl, V., Levenstein, M. E., Yu, J., Probasco, M. D., Thomson, J. A. Feeder-independent culture of human embryonic stem cells. Nature. 3, 637-646 (2006).
35. Chen, G., Gulbranson, D. R., et al. Chemically defined conditions for human iPSC derivation and culture. Nature methods. 8, (5), 424-429 (2011).
36. Kinney, M. A., Sargent, C. Y., McDevitt, T. C. The multiparametric effects of hydrodynamic environments on stem cell culture. Tissue engineering. Part B, Reviews. 17, 249-262 (2011).
37. Villa-Diaz, L. G., Ross, A. M., Lahann, J., Krebsbach, P. H. Concise review: The evolution of human pluripotent stem cell culture: from feeder cells to synthetic coatings. Stem cells (Dayton, Ohio). 31, (2013).
38. Park, I. H., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 451, (7175), 141-146 (2008).
39. Chambers, I., et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 113, (5), (2003).
40. Wright, A. J., Andrews, P. W. Surface marker antigens in the characterization of human embryonic stem cells. Stem cell research. 3, (1), 3-11 (2009).
41. Thomson, J. A Embryonic Stem Cell Lines Derived from Human Blastocysts. Science. 282, (5391), 1145-1147 (1998).
42. Mayshar, Y., et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell stem cell. 7, (4), 521-531 (2010).
43. Martins-Taylor, K., Xu, R. -H. Concise review: Genomic stability of human induced pluripotent stem cells. Stem cells(Dayton, Ohio). 30, (1), 22-27 (2012).
44. Okita, K., Ichisaka, T., Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature. 448, (7151), 313-317 (2007).
45. Aasen, T., et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nature. 26, (11), 1276-1284 (2008).
46. Lian, X., et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proceedings of the National Academy of Sciences of the United States of America. 109, (27), E1848-E1857 (2012).
47. Ludwig, T. E., et al. Derivation of human embryonic stem cells in defined conditions. Nature biotechnology. 24, (2), 185-187 (2006).
48. Wang, L., Li, L., Menendez, P., Cerdan, C., Bhatia, M. Human embryonic stem cells maintained in the absence of mouse embryonic fibroblasts or conditioned media are capable of hematopoietic development. Blood. 105, (12), 4598-4603 (2005).
49. Yu, J., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science(New York, N.Y.). 318, (5858), 1917-1920 (2007).
50. Kim, C. Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application. Blood research. 49, 7-14 (2014).
51. Jung, E. -M., et al. Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. Journal of applied toxicology: JAT. February. (2014).